Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey Cabos, hope your starting the year off right. In regards to the filings you were asking about.
All were tied to the previous 4 filed 9/29. The reason for them is listed below:
Represents shares withheld for payment of tax liability in connection with vesting of 50% of restricted stock units ("RSUs") granted to the reporting person on September 29, 2021 and previously reported on Form 4.
Hello Zippie, hope your New Year is starting off right. Not sure what you seek “What’s this say”
My initial thought is not much. One doesn’t translate to the other with any meaning with those values. Let’s say we just round the numbers here, 150 mil shares. 2 million short. Market cap 5.0 million. the short number has been running, for the most part between 1.5 to 3 percent all year. Meaningless. If it gets to 20 to 30 percent, then you could have a squeeze, or not depending on reason, but where it’s at and where it’s been, there is no there, there. The 5 million cap is just what the market and all included says it’s worth.
I like to think of CVSI as a company that has found a little niche in the overall 5-billion-dollar market. At 16 million in sales, they really don’t have much of an impact to the overall. Just one company in a sea of many. However, in their case the sales are falling and that’s the problem. There like a grocery store {yes, I know they make and sale product} but as an example the average grocery store in the US only makes $14 million in yearly revenue.” Oct 3, 2022.” That’s about the same as this company makes.
There are a lot of grocery stores across this country, and they simply don’t have that must have product to differentiate from the others, in CVSI they don’t have any way to control their environment nor is there any indication they have any game plan to do so. Dead in the water, heck just look at the trade numbers per day, they rarely get over 100k in dollars per day, a minimum for most traders to work with, again dead money. Until the volume comes way up, dollar wise, I wouldn’t pay to much attention to shorting, and the market cap value as it is, just shows that they are not any more than just a little niche company in a big sea of little companies. IMO
Ahhhh Wolfy, All CVSI has to do is sell more product and do so profitably while cutting the SG&A. They haven’t been able to do that. Qt after QT for 3 years in a row, falling sales every qt. All the story telling, the wink here, nod there don’t mean jack. They can blame whatever they want for the poor showing, at the end of the day, results matter and story telling is something better suited for books.
As the sales fall, so does the share price. See if you can dial that one in. See if that might be a clue for you. Sales, profits, results, everything else is BS. Until they do, it's just another utter failure. IMO
I know. Opportunity lost and what an opportunity it was too. In your baseball terms, it was like mighty Casey first up and at the bat, only to strike out. CVSI shouting I could have been a contender, but alas they never learned how to sell it. Quarter after quarter of falling sales for 3 years in a row brings us to this point. A 3-cent stock. At the end of the day after all the words have been spoken, we have a company that just is unable to sell their product, come out with new products, sure, does sales still fall, you bet! End of that opportunity. Now dead in the water.
Alright let's see if CVSI can hold than 0.03 mark. Go team go.
FDA, making a mistake, hmmmmmmm well it would take some time indeed to sore thru them all. Fun fact, 70 percent of the FDA funding comes from big pharma. It begs the question why would big pharma fund the FDA and regulate same only to shut them down when they come out with a less than healthy product. In 1995 they approved opioids.
A little back ground:
Prescription opioids are powerful pain-reducing medications that include oxycodone, hydrocodone, and morphine, among others, and have both benefits as well as potentially serious risks. However, too many Americans have been impacted by the serious harms associated with these medications, and despite ongoing efforts, the scope of the opioid crisis continues to grow.
One of the highest priorities of the FDA is advancing efforts to address the crisis of misuse and abuse of opioid drugs harming families. Opioids are claiming lives at a staggering rate, and overdoses from prescription opioids are reducing life expectancy in the United States.
At FDA, we’re working across the full scope of our regulatory obligations to impact this crisis. Our approach to reducing the misuse and abuse of opioids is outlined in FDA’s 2018 Strategic Policy Roadmap, which addresses various facets of this complex issue, as there are no simple answers to reverse this epidemic.
You see, for the last 5 years they have that SP roadmap running, so problem solved?
Also since you mentioned it. Nope never shorted this stock. EVER !!
Since you brought it up lets look. https://www.wanabrands.com/
Nope, clearly they are into a broad range including CBD. Far more options than CVSI. Kind of the current trend isn't it.
See the price they paid for it?
The reason CGC did of course is to be set up for listing once legal gets done. AS THEY HAVE STATED!
You were better off with the inventive talk on Nept. There getting out of that product but it sure sounded good on all that happy talk you did.
Thats a good catch, thanks!
LOL, now that's funny.
You know you can buy 34 shares for a buck, but then again why waste a buck. It's a fair question.
Merry Xmas.
LOL. 150 million shares, only 2 million short, same as last month. But I had to go back and look. Why are you showing what the short interest was 12/1. 25 days ago?
Well how about this, you claim you were in since 2019. So from 1/1/2019 till now. Does look a lot better. Only down a little over 99.3 percent. That’s about as pretty as I can make it look. Now if you bought in March or April it would have been worst than the 99.3, but again wanted to to make it starting at the 1st. So it looks like congrats you WIN!.
CVSI chart is not looking good. A person can could be inventive, tell stories or just make things up, but at the end of the day the charts will tell you the story. They never lie.
He’s one for you.
And another wrong one from the wolfy- The Shorts can only increase the PPs in order to cover for a LOSS and then the Pps comes back to its equilibrium. On Monday the bid and ask went to.04 by .045 before it came back down to the original ask of.038. The SHORTS realize that CVSI can go no lower.
Since your post a couple of weeks ago it’s dropped 31 percent. How is it you can be that wrong?
Dead center perfect. Old wolfy posted : WISE WQLF SAID ; Just think, the WOKE CVSI Statistician who stated that the CVSI PPS will be in the two’s on account of CVSI shareholders selling masses of their shares by the end of the year for tax write offs is far off his or hers chart YQU Understand.
Well, here we are in the 0.02’s. Charts working perfectly.
Well, CVSI is in an interesting position heading into next year. I think 2023 and maybe into 2024 will be the time of buyouts and die outs. Read somewhere there are over 10,000 companies selling CBD products and that makes me wonder how are they staying in business. We don’t have all 10k operating at a loss, do we? As we head into the recession, I think we’ll see a reduction of the above number. I also think we will finally get into the price compression stage as companies try and maintain market share vs the competition. I don’t think we’ll get any help from the FDA anytime soon, so. Currently CVSI is at a market cap of 4.6 million, which is interesting since they claim an inventory of product valued at 7 million. Bad cash management? They do have a net income of neg- 15 million, not so good. They do have a few tools to use. Roughly 650 million more shares to dilute with and a up to a rev. split of 1 for 400 that is authorized but they haven’t pulled the trigger on yet. On the other hand, if they keep on losing sales what’s the point. Buy out or die out. Place your bets. IMO
Well, got filled now. Just above 50 flat. Funny thing is it went lower a few times but for whatever reason didn't fill. Broke it up some and here we are.
Just coming off the oversold is all. or in keeping with your theme
"Paranoia strikes deep
Into your life, it will creep
It starts when you're always afraid
Step out of line, the man come and take you away"
For what it's worth 1967, great song.
Well, lets see if I can filled today. Here's hoping.
Well, the volume has been dropping off nicely but we still don’t have a move up. Perhaps a consolidation phase will be needed.
Another hit me up with this today. I'll repost here -- https://s3.documentcloud.org/documents/23506988/2022-12-22-letter-urging-recognition-of-merits-of-descheduling-1_0.pdf
Another hit me up with this today. I'll repost here -- https://s3.documentcloud.org/documents/23506988/2022-12-22-letter-urging-recognition-of-merits-of-descheduling-1_0.pdf
Thanks for that, hopefully it will do some good.
There are several levels that can be viewed with this, however as stated we won't have the full details until they file the 4th qt numbers. We'll see.
I'm all for it but it seems they have a habit of backing SAFE of of the deals before it comes to vote. We'll see.
Put a bid in today, see if it hits.
That is an honorable way to run a business. Not many in this day and age would do that. It’s old school.
River’s makes 4.3, hmmmm. I did not know that but she is a long way away from proving her worth. The game nowadays is to run hot and fast. She has proven she knows how to expand, but at what cost, she is racking up huge debt, private placement notes over ½ billion worth and deferring taxes, ¼ billion worth and with that she still has yet to turn a profit. I would think a cut all around in management pay to retain the workers would be a better long-term play for a fresh company as this is.
But I was trained in a different direction than what is being done today. I learned the ropes from a guy by the name of Jack Welch or as we knew him Neutron Jack. No nonsense tough, if you couldn’t get it done you were gone, everybody got rated, if you were in the lower 10 percent, regardless of how good you were, you were gone. On the other hand, if you were in the top 20 percent you were taken care of pretty good. It was tough there, but also fair, if you could work. If you couldn’t, if you were a slacker, there was no place to hide. Things running thru my head right now, Six Sigma, the saying lower head count, higher work load, black belt projects, master black belt projects, I’ll say this you learn a lot of how to run a business, and some did leave to run as CEO’s of other businesses, and many more as upper management, but that is a different era than today. As far as River’s goes, all she has to do is produce a strong enough profit that can justify her wage. However, currently were losing money and building debt so the jury is still out. IMO
This Cannabis Multi-State Operator Was The Only One With Solid Profits In The Last Quarter
8:05 am ET December 21, 2022 (Benzinga) Print
Most U.S. cannabis multistate operators reported modest to significant year-over-year revenue gains.
Among the companies with the highest revenue in the third quarter were Curaleaf Holdings (OTC: CURLF) with $339 million followed by Trulieve Cannabis (OTC: TCNNF) with $300 million.
In a similar range was Green Thumb Industries (OTC: GTBIF) with $261 million, Verano Holdings (OTC: VRNOF) ($228M), and Cresco Labs (OTC: CRLBF) ($210M), followed by Columbia Care (OTC: CCHWF) with $132M, Ayr Wellness (OTC: AYRWF) with $119.6M, Ascend Wellness Holdings (OTC: AAWH) ($111M), Jushi Holdings (OTC: JUSHF) ($72.8M), TerrAscend (OTC: TSRRF) ($67M) and Acreage Holdings (OTC: ACRHF) ($61.4).
Those with a presence in emerging markets, such as New Jersey, experienced significant year-over-year growth in revenues in the third quarter of 2022. According to MJBizDaily Curaleaf increased its revenues by 7%, Green Thumb Industries by 11.8%, Verano Holdings by 10%, Columbia Care by 0.3%, Ascend Wellness by 17.9%, TerrAscend 36.4% and Acreage Holdings by 28%.
This Cannabis Multi-State Operator Was The Only One With Solid Profits In The Last Quarter
8:05 am ET December 21, 2022 (Benzinga) Print
Most U.S. cannabis multistate operators reported modest to significant year-over-year revenue gains.
Among the companies with the highest revenue in the third quarter were Curaleaf Holdings (OTC: CURLF) with $339 million followed by Trulieve Cannabis (OTC: TCNNF) with $300 million.
In a similar range was Green Thumb Industries (OTC: GTBIF) with $261 million, Verano Holdings (OTC: VRNOF) ($228M), and Cresco Labs (OTC: CRLBF) ($210M), followed by Columbia Care (OTC: CCHWF) with $132M, Ayr Wellness (OTC: AYRWF) with $119.6M, Ascend Wellness Holdings (OTC: AAWH) ($111M), Jushi Holdings (OTC: JUSHF) ($72.8M), TerrAscend (OTC: TSRRF) ($67M) and Acreage Holdings (OTC: ACRHF) ($61.4).
Those with a presence in emerging markets, such as New Jersey, experienced significant year-over-year growth in revenues in the third quarter of 2022. According to MJBizDaily Curaleaf increased its revenues by 7%, Green Thumb Industries by 11.8%, Verano Holdings by 10%, Columbia Care by 0.3%, Ascend Wellness by 17.9%, TerrAscend 36.4% and Acreage Holdings by 28%.
Trulieve Announces Closing of $71.5 Million Financing
3:49 pm ET December 21, 2022 (PR Newswire) Print
Trulieve Cannabis Corp.(CSE: TRUL) (OTCQX: TCNNF)("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the closing of a commercial loan secured by a cultivation and manufacturing site in Florida for aggregate gross proceeds of $71.5 million. Trulieve will pay interest at a fixed rate of 7.53% for the duration of the five-year loan. Lenders were comprised of three banks, with Valley National Bank serving as lead agent. The Company intends to use the net loan proceeds for general corporate purposes.
https://mma.prnewswire.com/media/1720011/Trulieve_Logo.jpg
"We are pleased to announce this non-dilutive financing at industry leading terms, particularly given the current macroeconomic backdrop," said Trulieve Chief Executive Officer, Kim Rivers. "This loan provides Trulieve greater flexibility as we focus on improving cash flow in 2023."
"We're proud to partner with Trulieve, one of the leading providers in the medical and recreational cannabis industry," remarked John Meyer, Senior Vice President of Commercial Lending at Valley Bank. "As one of the premier commercial banks in the country, Valley has a wide array of innovative financial solutions to serve every industry, including cannabis related businesses like Trulieve. We believe our relationship-based banking model was a differentiator in structuring this commercial loan with Trulieve and we're excited to support them as they continue to grow and expand into new markets."
About Valley As the principal subsidiary of Valley National Bancorp, Valley National Bank is a regional bank with nearly $56 billion in assets. Valley is committed to giving people and businesses the power to succeed. Valley operates many convenient branch locations and commercial banking offices across New Jersey, New York, Florida, Alabama, California, and Illinois, and is committed to providing the most convenient service, the latest innovations and an experienced and knowledgeable team dedicated to meeting customer needs. Helping communities grow and prosper is the heart of Valley's corporate citizenship philosophy. To learn more about Valley, go to www.valley.com or call our Customer Care Center at 800-522-4100.
The reason for hope on SAFE Banking is both obvious and irritating: It's inevitable.
The SAFE Banking Act is dead. For now.
Though many in the cannabis trade are understandably frustrated – particularly given how much hope there was the past two years that Congress had finally reached a tipping point on marijuana – it’s worth remembering that almost nothing in Washington, D.C. happens overnight.
It’s usually the opposite. That’s been particularly true in the past decade, which has seen Congress devolve into arguably the most partisan and fractured landscape in modern history, in which annual standoffs over the federal budget have become mainstays.
The reason for hope on SAFE Banking is both obvious and irritating: It’s inevitable.
That’s plain just by looking at the national map of how many states have legalized cannabis, and thus have stakeholders who are complaining to their senators and representatives about the inequities they labor under due to the federal illegality of cannabis.
And marijuana reform is perhaps one of the only truly nonpartisan topics in the capitol – the SAFE Banking Act itself is a prime example. The House version of the bill has 26 Republican co-sponsors out of the 180 representatives that championed the bill, and the Senate version has nine GOP co-sponsors accompanying the 31 Democratic sponsors.
Not only that, but the issue is a generational one, with younger Republicans such as Reps. Nancy Mace (R-South Carolina), Dave Joyce (R-Ohio), and Matt Gaetz (R-Florida) openly pushing cannabis legislation, while it’s largely the older lawmakers on both sides of the aisle that tend to shy away from the issue.
In addition, Senate Majority Leader Chuck Schumer (D-New York) has already pledged to “go back at it next year” with SAFE.
While Schumer may have lost some credibility in cannabis circles this year with his failure to advance his own marijuana legalization bill, he’s far from the only senator who wants to see cannabis reform become a reality.
Incoming Pennsylvania Sen. John Fetterman, for instance, campaigned hard on federal cannabis legalization this election season, and Sens. Cory Booker of New Jersey and Ron Wyden of Oregon have also both made cannabis reform a major priority.
On top of that, Congress just this year approved – and President Joe Biden signed into law – its first marijuana reform bill since cannabis was federally banned: The Medical Marijuana and Cannabidiol Research Expansion Act.
So industry insiders can choose whichever metaphor they like – the toothpaste is out of the tube, the genie is out of the bottle – but the bottom line is that cannabis prohibition is over. The question is only when Congress will get its act together. Not if.
Yes, 1 year scale. allows for a detailed breakdown of what I'm looking for.